Lilly’s Phase 3 EMBER-3 trial results set to shake up breast cancer treatment landscape
Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader (SERD), at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13. This late-breaking presentation marks the first time EMBER-3 data will be publicly shared. EMBER-3 is evaluating imlunestrant as […]